Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beam Therapeutics Inc. (BEAM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer. Beam files reports and current reports with the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events related to its precision genetic medicines platform.
Investors can review Form 8-K filings in which Beam reports items such as quarterly financial results and significant transactions. For example, the company has used Form 8-K to furnish press releases announcing results for quarters ended June 30 and September 30, and to disclose an Agreement and Plan of Merger under which it acquired an early-stage life sciences company in exchange for upfront shares and potential milestone-based consideration.
In addition to 8-Ks, Beam’s periodic reports on Form 10-K and Form 10-Q (accessible via EDGAR and summarized on this page when available) typically include information on its base editing platform, programs such as risto-cel (formerly BEAM-101), BEAM-302 and BEAM-301, risk factors, liquidity and capital resources. These filings also describe regulatory designations, clinical trial status and collaboration arrangements that are important for understanding the company’s development-stage business.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures on topics like clinical milestones, cash runway, collaboration agreements and equity issuances. Real-time updates from EDGAR ensure that new Beam filings, including any future Forms 4 reporting insider transactions or proxy statements on executive compensation and governance, are surfaced promptly.
By combining official SEC documents with AI-generated overviews, this page helps investors and researchers analyze Beam’s regulatory history, financial reporting and material events that influence the BEAM stock narrative.
Beam Therapeutics Inc. CEO John M. Evans reported an automatic sale of 30,078 shares of common stock on April 1, 2026 at $24.58 per share. According to the disclosure, these shares were sold in a non-discretionary transaction solely to cover tax withholding obligations tied to previously granted restricted stock units under the company’s 2019 Equity Incentive Plan, pursuant to a Rule 10b5-1 trading plan adopted in May 2023. Following this transaction, Evans directly holds 1,047,205 shares and indirectly holds 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which total includes 616 shares acquired under the company’s amended and restated 2019 Employee Stock Purchase Plan on March 31, 2026.
Beam Therapeutics Inc. Chief Medical Officer Amy Simon reported an open-market sale of 6,700 shares of common stock at $24.58 per share. According to the filing, these shares were automatically sold to cover tax withholding obligations tied to vesting of restricted stock units under Beam’s 2019 Equity Incentive Plan and were executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Simon directly holds 102,735 Beam shares, and the total includes shares acquired through the company’s Employee Stock Purchase Plan.
Beam Therapeutics SVP Finance Bethany J. Cavanagh reported an automatic sale of common stock mainly to cover taxes on vesting equity awards. On April 1, 2026, 3,242 shares were sold in an open-market transaction at $24.58 per share. These shares were sold to satisfy tax withholding obligations tied to restricted stock units granted under the company’s 2019 Equity Incentive Plan that vested on multiple March 31 dates from 2022 through 2025. Following the sale, Cavanagh directly holds 51,171 Beam Therapeutics shares. The filing notes the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024, indicating the timing was set in advance rather than chosen opportunistically.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share. After this transaction, she directly holds 109,711 shares of Beam Therapeutics common stock.
The shares were sold in a non-discretionary transaction solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on March 31 of 2022, 2023, 2024 and 2025 under the company’s 2019 Equity Incentive Plan. The sales were effected under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the trades were pre-planned rather than opportunistic market sales.
Beam Therapeutics President Giuseppe Ciaramella reported an automatic sale of 11,810 shares of common stock at $24.58 per share. The shares were sold to cover tax withholding obligations tied to previously granted restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, he directly holds 218,406 shares of Beam Therapeutics common stock.
Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units (RSUs) of common stock on March 31, 2026. Each RSU equals one share and was granted at no cash cost to her.
The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the grant date, conditioned on her continued service with Beam. After this award, she holds 115,667 shares of Beam common stock directly, reflecting a routine, compensation-related equity grant rather than an open-market purchase.
Cavanagh Bethany J reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received a grant of 20,000 restricted stock units under the company’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments, subject to continued service. Following this award, she holds 54,813 shares directly.
Simon Amy reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. granted Chief Medical Officer Amy Simon 31,750 restricted stock units (RSUs), each representing the right to receive one share of Beam common stock. The RSUs vest in four substantially equal annual installments on the first four anniversaries of the grant date, conditioned on her continued service. Following this award, she directly holds 109,114 shares of Beam common stock, reflecting a compensation-related equity grant rather than an open-market transaction.
Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that its Chief Financial Officer, Sravan Kumar Emany, received a grant of 31,750 shares of common stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in four substantially equal annual installments, starting on the first anniversary of the grant date, if he continues serving at the company. Following this award, his directly held common stock position is 105,456 shares, reflecting compensation tied to long-term service and company performance.
Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that President Giuseppe Ciaramella received an equity grant of 40,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one Beam share and will vest in four substantially equal annual installments, subject to his continued service. Following this award, he directly holds 230,216 shares of Beam common stock, including the RSUs.